Addition of Pembrolizumab to Standard Chemotherapy Patients with Early-Stage Triple-Negative Breast Cancer Has the Potential for a New Standard of Care

After over six years of follow-up, pembrolizumab added to chemotherapy significantly improves event-free and overall survival in triple-negative breast cancer. The KEYNOTE-522 trial, presented by Peter Schmid at ESMO 2024 as a late breaking abstract (LBA4).